Daily Watch List: Nidec Corporation (NYSE:NJ), California First National Bancorp (NASDAQ:CFNB), CorMedix (NYSEMKT:CRMD), vTv Therapeutics (NASDAQ:VTVT)

Avon Products Inc. (NYSE:AVP) shares moved up 2.14% in last trading session and ended the day at $3.81. AVP Gross Margin is 60.30% and its has a return on assets of -28.90%. Avon Products Inc. (NYSE:AVP) quarterly performance is 14.41%.

Nidec Corporation (NYSE:NJ) ended the last trading day at $16.74. Company weekly volatility is calculated as 1.42% and price to cash ratio as 6.96. Nidec Corporation (NYSE:NJ) showed a weekly performance of 2.39%.

Nidec Corporation (NYSE:NJ) announced that Mr. Mutsuo Tahara, a valued outside member of the Company’s Board of Directors, passed away on February 19, 2016. Mr. Mutsuo Tahara had served on the Company’s Board of Directors since June 2014 and provided the Company with valuable insights based on his rich professional background in law.

On 29 February, California First National Bancorp (NASDAQ:CFNB) shares fell -3.12% and was closed at $13.05. CFNB EPS growth in last 5 year was -4.20%. California First National Bancorp (NASDAQ:CFNB) year to date (YTD) performance is -1.29%.

RBC Capital restated their sector perform rating on shares of California First National Bancorp (NASDAQ:CFNB) in a research report report published on Friday. RBC Capital currently has a $24.00 price target on the financial services provider’s stock, up from their previous price target of $23.00.

CorMedix, Inc. (NYSEMKT:CRMD) shares fell -12.78% in last trading session and ended the day at $1.57. CRMD Gross Margin is -33.30% and its has a return on assets of -71.00%. CorMedix, Inc. (NYSEMKT:CRMD) quarterly performance is -31.74%.

CorMedix Inc. (NYSE MKT: CRMD), pleased to provide a summary of its 2015 business accomplishments and its 2016 anticipated activities and objectives. – Initiated United States pivotal Phase 3 clinical “LOCK-IT 100” (Catheter Lock Solution Investigational Trial) of Neutrolin® for hemodialysis patients with central venous catheters. Multi-center, randomized, double-blind, active-controlled trial designed to enroll up to 632 patients. Designed to demonstrate safety and efficacy of Neutrolin for preventing catheter-related bloodstream infection in patients on hemodialysis for end-stage renal disease with robust statistical significance.

vTv Therapeutics Inc. (NASDAQ:VTVT) caters to the Healthcare space. Its weekly performance is -12.29%. On the last day of trading company shares ended up at $5.71.

vTv Therapeutics Inc. (NASDAQ: VTVT) announced that data from studies of its oral, small molecule GLP-1R agonist were reported at the Keystone Symposia on G-Protein Coupled Receptors: Structure, Signaling and Drug Discovery, held in Keystone, CO February 21-25, 2016.